Related Experiment Video

Updated: Aug 30, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Grb7-based molecular therapeutics in cancer

Stephanie C Pero1, Roger J Daly, David N Krag

  • 1Department of Surgery and the Vermont Cancer Center, University of Vermont School of Medicine, Given Medical Building, Burlington, VT 05405, USA. Stephanie.Pero@uvm.edu

Expert Reviews in Molecular Medicine
|October 31, 2003
PubMed

Insights

Targeting Grb7, a signaling protein overexpressed in several cancers, offers a promising strategy to inhibit cancer cell proliferation and invasion. Developing inhibitors against Grb7 could lead to more effective cancer therapies with fewer side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Traditional chemotherapy lacks specificity, causing severe side effects by affecting normal cells.
  • Signal transduction molecules are key targets for developing selective anti-cancer therapies.
  • Grb7 (Growth factor receptor-bound protein 7) is implicated in cancer cell proliferation, migration, and invasion.

Purpose of the Study:

  • To highlight Grb7 as a potential therapeutic target for cancer treatment.
  • To explore the role of Grb7 in cancer progression.
  • To identify molecular interactions involving Grb7 for drug development.

Main Methods:

  • Review of literature on Grb7 function and overexpression in various cancers.
  • Analysis of Grb7's role as an adaptor protein in signal transduction pathways.
  • Investigation of Grb7's interaction with tyrosine kinases via its SH2 domain.

Main Results:

  • Grb7 is overexpressed in breast, oesophageal, and gastric cancers.
  • Grb7's adaptor function facilitates signaling pathways crucial for cancer cell phenotypes.
  • Grb7's involvement in tyrosine kinase signaling contributes to cancer invasiveness.

Conclusions:

  • Grb7 is a significant contributor to cancer cell invasiveness and progression.
  • Targeting Grb7 and its molecular interactions presents a viable therapeutic strategy.
  • Inhibiting Grb7 offers a potential approach for developing targeted cancer therapies with reduced side effects.

More Related Videos

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...